Seoul, South Korea/Rockville, MD; March 30, 2009: HanAll Biopharma, a leading Korean-based and global R&D company, announces that its patent application entitled ‘PROTEASE RESISTANT MODIFIED GROWTH HORMONE POLYPEPTIDES’ has received notice of allowance from the U.S. Patent and Trademark Office.
This will be the second issuance of several patent applications related to its Next Generation Protein Therapeutic Program. HanAll is developing a pipeline of long-acting injectable and “oral” proteins which includes interferon-alpha2b, interferon-beta, human growth hormone, EPO, anti-TNF alpha peptide and antibody fragment.
Through its high throughput 2-D and 3-D scanning technology, parent molecules are modified through point mutations (amino acid substitution) to produce resistance to serum and GI proteases while maintaining or significantly improving their PK/PD profile. With molecules that are resistant to proteolysis, the goal is to produce the next generation of injectable proteins with superior efficacy and PK profiles compared to current proteins but also to develop the first generation of oral protein therapeutics.
HanAll has also received a U.S. patent issuance for Hanferon™ (modified interferon-alpha) as well as notice of allowance from the European Patent Office.
About HanAll Biopharma Co., Ltd.
HanAll is a Korean-based R&D pharmaceutical company with corporate development offices in Rockville, MD and Philadelphia, PA. With 2009 turnover of USD $100 million, HanAll is a leader in R&D for the global development of innovative products in the areas of protein therapeutics, cardiovascular fixed-dose combination products, oncology and dermatology. Under an active U.S. IND, the company is planning the initiation of a Phase Ib/IIa clinical trial to demonstrate the superior PK/PD profile of a next generation, single point mutated interferon-alpha (Hanferon™ SC) for the treatment of hepatitis C virus infections. Protein therapeutics for oral administration are also in development (active U.S. IND) utilizing point mutation of known proteins that produces resistance to GI and serum protease degradation.
HanAll has begun enrollment to support a Phase I trial in Korea to demonstrate the unique time-delayed release profile of HL 007, a combination of simvastatin (immediate release) and amlodipine (delayed release). Next generation formulations of biguanide derivatives for adjuvant cancer treatment are also under development. HanAll is seeking co-development or exclusive licensing partners to support the development and commercialization of it product programs.
For more information please contact Andrew J. Gorman, VP & Chief, Corporate Development (301-738-3980, ajgorman@hanall.co.kr) or visit our website at www.hanallbiopharma.com
